[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
[HTML][HTML] Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials …
…, AM Collins, R Cooper, WEM Crocker, TC Darton… - The Lancet, 2021 - thelancet.com
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …
immunity in some countries as the interval between the first and second dose becomes …
An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate …
CS Waddington, TC Darton, C Jones… - Clinical Infectious …, 2014 - academic.oup.com
Background. Typhoid fever is a major global health problem, the control of which is hindered
by lack of a suitable animal model in which to study Salmonella Typhi infection. Until 1974, …
by lack of a suitable animal model in which to study Salmonella Typhi infection. Until 1974, …
[HTML][HTML] Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study
Background Enteric fever is a serious public health concern in many low-income and middle-income
countries. Numerous data gaps exist concerning the epidemiology of Salmonella …
countries. Numerous data gaps exist concerning the epidemiology of Salmonella …
Ethics of controlled human infection to address COVID-19
Development of an effective vaccine is the clearest path to controlling the coronavirus disease
2019 (COVID-19) pandemic. To accelerate vaccine development, some researchers are …
2019 (COVID-19) pandemic. To accelerate vaccine development, some researchers are …
Design, recruitment, and microbiological considerations in human challenge studies
TC Darton, CJ Blohmke, VS Moorthy… - The Lancet infectious …, 2015 - thelancet.com
Since the 18th century a wealth of knowledge regarding infectious disease pathogenesis,
prevention, and treatment has been accumulated from findings of infection challenges in …
prevention, and treatment has been accumulated from findings of infection challenges in …
[HTML][HTML] Omicron BA. 1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
Background The omicron BA.1 bivalent booster is used globally. Previous open-label studies
of the omicron BA.1 (Moderna mRNA-1273.214) booster showed superior neutralising …
of the omicron BA.1 (Moderna mRNA-1273.214) booster showed superior neutralising …
[HTML][HTML] Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with …
TC Darton, C Jones, CJ Blohmke… - PLoS neglected …, 2016 - journals.plos.org
Background Typhoid persists as a major cause of global morbidity. While several licensed
vaccines to prevent typhoid are available, they are of only moderate efficacy and unsuitable …
vaccines to prevent typhoid are available, they are of only moderate efficacy and unsuitable …